Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study
Regina Dittmann(Forschungszentrum Jülich), David Coghill(The University of Melbourne), Beatriz Caballero, Nicholas Higgins(Takeda (United States)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Richard Civil(Takeda (United States)), Colleen Anderson(Takeda (United States)), Paul Hodgkins(Takeda (United States)), Péter Nagy(Vadaskert Alapítvány a Gyermekek Lelki Egészségéért), Esther Cardo(Hospital Son Llatzer), A. G. Lyne(University of Manchester)
Cited by 88
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Tests of General Relativity from Timing the Double Pulsar
|Science|2006|1.1k